Literature DB >> 2513206

Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris.

M Picca1, F Azzollini, A Cereda, G Pelosi.   

Abstract

The antianginal effects of propranolol 160 mg/day, diltiazem 240 mg/day, nicardipine 80 mg/day, nifedipine 40 to 80 mg/day and verapamil 320 mg/day were compared in 12 patients with chronic stable angina pectoris using a symptom-limited exercise test. Compared to placebo propranolol and calcium antagonists similarly reduced (p less than 0.001) the frequency of antianginal attacks and nitroglycerin consumption, and increased exercise tolerance and time to greater than or equal to 1 mm S-T segment depression. After propranolol the pressure-rate product at submaximal and maximal exercise was significantly decreased. The calcium antagonists produced a significant reduction in the submaximal pressure-rate product, but no significant change in the peak pressure-rate product. Maximum ST depression was significantly lower after propranolol and was unchanged after the calcium antagonists. None of the drugs caused significant adverse effects. The results indicate that in patients with stable effort angina pectoris, diltiazem, nicardipine, nifedipine and verapamil were as effective as propranolol in improving exercise tolerance and time to ischaemia, and they did not alter the peak pressure-rate product. Different antianginal mechanisms may be operative for the various calcium antagonists.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2513206     DOI: 10.1007/bf00558494

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  44 in total

1.  Multicenter trial of propranolol in angina pectoris.

Authors:  R H Grant; P Keelan; R J Kernohan; J C Leonard; L Nancekievill; K Sinclair
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

2.  Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients with severe angina of effort.

Authors:  M D Winniford; R L Huxley; L D Hillis
Journal:  J Am Coll Cardiol       Date:  1983-02       Impact factor: 24.094

3.  Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris.

Authors:  M B Leon; D R Rosing; R O Bonow; L C Lipson; S E Epstein
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

4.  A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina.

Authors:  N N Sadick; A T Tan; P J Fletcher; J Morris; D T Kelly
Journal:  Circulation       Date:  1982-09       Impact factor: 29.690

5.  Long-term propranolol therapy for angina pectoris.

Authors:  S G Warren; D L Brewer; E S Orgain
Journal:  Am J Cardiol       Date:  1976-03-04       Impact factor: 2.778

6.  Dose response effectiveness of propranolol for the treatment of angina pectoris.

Authors:  E L Alderman; R O Davies; J J Crowley; M G Lopes; J Z Brooker; J P Friedman; A F Graham; H J Matlof; D C Harrison
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

7.  Verapamil versus placebo in relieving stable angina pectoris.

Authors:  M B Pine; P D Citron; D J Bailly; S Butman; G O Plasencia; D W Landa; R K Wong
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

8.  Improved exercise tolerance after propranolol, diltiazem or nifedipine in angina pectoris: comparison at 1, 3 and 8 hours and correlation with plasma drug concentration.

Authors:  B R Chaitman; P Wagniart; A Pasternac; G Brevers; J M Scholl; J Lam; M Methe; R J Ferguson; M G Bourassa
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

9.  Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing.

Authors:  B Subramanian; M Bowles; A Lahiri; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

10.  Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.

Authors:  C de Ponti; F Mauri; G R Ciliberto; B Carù
Journal:  Eur J Cardiol       Date:  1979-07
View more
  2 in total

Review 1.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 2.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.